The Gm9766 Inhibitors chemical class encompasses a range of compounds characterized by their ability to interact with and modulate cellular signaling pathways, thus potentially influencing the activity of proteins similar to those encoded by the gene Gm9766. Each compound within this class operates through a specific mechanism of action, targeting key components of cellular pathways and offering diverse potential effects on protein function.
Trametinib, a MEK inhibitor, along with Cobimetinib, Selumetinib, and Binimetinib, exemplify the class's capacity to disrupt the MAPK/ERK signaling pathway. This pathway plays a crucial role in regulating cell growth, differentiation, and survival, processes that are intimately linked to the regulation and function of various proteins, including those potentially similar to Gm9766. By modulating this pathway, these inhibitors can significantly impact protein activity.
Dabrafenib, Encorafenib, Vemurafenib, and other BRAF kinase inhibitors within this class, such as Braftovi and Tafinlar, demonstrate the class's influence on cell signaling related to proliferation and survival. These compounds target specific kinases involved in signaling pathways that are critical for cellular communication and response to environmental cues, thereby potentially affecting protein functions related to these processes.
Ulixertinib targets the ERK1/2 proteins, further highlighting the class's role in modulating the MAPK/ERK pathway, a key regulator of cell signaling. Zelboraf, specifically targeting BRAF V600E mutation, underscores the class's potential to disrupt specific signaling pathways that are altered in certain pathological conditions.
Collectively, the Gm9766 Inhibitors represent a diverse array of compounds capable of interacting with a wide range of cellular mechanisms. These interactions, through their modulation of key signaling pathways and cellular processes, provide valuable insights into how such compounds could influence the function of proteins akin to those encoded by Gm9766. The extensive potential of these inhibitors in influencing protein activity underscores the complex nature of cellular signaling and its impact on protein function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor, Trametinib can disrupt MAPK/ERK signaling pathways, potentially affecting protein activity. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Targets MEK1/MEK2, Cobimetinib can modulate cell signaling pathways, influencing protein functions. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Inhibits MEK1/2, Selumetinib can affect cell growth and differentiation pathways, impacting protein activity. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
A MEK inhibitor, Binimetinib can modulate MAPK/ERK pathway, affecting protein functions related to Gm9766. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Targets BRAF kinases, Dabrafenib can disrupt cell signaling, potentially influencing protein activity. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Inhibits BRAF kinases, Encorafenib can affect cell proliferation and survival pathways. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
A BRAF kinase inhibitor, Vemurafenib can modulate cell signaling pathways, impacting protein function. | ||||||
Ulixertinib | 869886-67-9 | sc-507296 | 10 mg | $176.00 | ||
Targets ERK1/2, Ulixertinib can influence the MAPK/ERK signaling pathway, affecting protein activity. | ||||||